|
Myasthenia Gravis
|
|
0.030 |
GeneticVariation
|
BEFREE |
There is association of rs733618 with the general susceptibility of MG, and association of rs231775 and rs3087243 with the susceptibility of ocular onset MG, but no association with the severity of MG.
|
31473094 |
2019 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
rs231775, rs4553808 and rs5742909 but not rs3087243 and rs733618 were significantly related to cancer risk.
|
29794444 |
2018 |
|
Myasthenia Gravis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Our results indicated that rs231775 and rs733618 were associated with higher risks of MG, providing potential references for future case-control studies.
|
30009380 |
2018 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
rs231775, rs4553808 and rs5742909 but not rs3087243 and rs733618 were significantly related to cancer risk.
|
29794444 |
2018 |
|
Myasthenia Gravis
|
|
0.030 |
GeneticVariation
|
BEFREE |
Genetic interaction analysis revealed a synergistic effect of CHRNA1 (rs16862847), AIRE (rs3761389), and CTLA-4 (rs733618) in the susceptibility of MG (P < 0.0001, OR = 1.95).
|
27501803 |
2017 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
We investigated the association of five CTLA4 single-nucleotide polymorphisms (SNPs) (rs733618 C/T, rs4553808 A/G, rs5742909 C/T, rs231775 A/G, and rs3087243 G/A) with de novo malignancy in 1463 Chinese renal transplantation (RT) recipients who underwent a 192-month follow-up.
|
25667935 |
2015 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
We investigated the association of five CTLA4 single-nucleotide polymorphisms (SNPs) (rs733618 C/T, rs4553808 A/G, rs5742909 C/T, rs231775 A/G, and rs3087243 G/A) with de novo malignancy in 1463 Chinese renal transplantation (RT) recipients who underwent a 192-month follow-up.
|
25667935 |
2015 |
|
Primary malignant neoplasm
|
|
0.030 |
GeneticVariation
|
BEFREE |
Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) -1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis.
|
24710335 |
2014 |
|
Malignant Neoplasms
|
|
0.030 |
GeneticVariation
|
BEFREE |
Lack of association between cytotoxic T-lymphocyte antigen 4 (CTLA-4) -1722T/C (rs733618) polymorphism and cancer risk: from a case-control study to a meta-analysis.
|
24710335 |
2014 |
|
Thyroid associated opthalmopathies
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, the genotype frequency of "TT" genotype in rs733618 significantly differed between patients with GO and healthy controls (OR = 0.421, 95%CI: 0.290-0.611, <i>p</i> = 0.043), and the "CC" and "CT" genotype in rs16840252 were nearly significantly differed in genotype frequency (<i>p</i> = 0.052).
|
31684013 |
2019 |
|
Multiple Myeloma
|
|
0.010 |
GeneticVariation
|
BEFREE |
CTLA-4 rs733618 GG reduced the progression-free survival and the overall survival of patients with MM who received bortezomib-based therapy.
|
29264740 |
2018 |
|
Breast Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, the -1661A>G (rs4553808) polymorphism increased breast cancer risk in allelic, heterozygous and dominant models, whereas -1722 T>C (rs733618) did not relate to breast cancer risk.
|
28097051 |
2017 |
|
Non-Small Cell Lung Carcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
However, the stratified analyses suggested CTLA-4 rs733618 vatiants were correlated with the development of NSCLC in ≥ 60 years subgroup (TC vs. TT: adjusted OR = 1.45, 95% CI = 1.04-2.02, <i>P</i> = 0.030) and even drinking subgroup (TC vs. TT: adjusted OR = 2.27, 95% CI = 1.11-4.60, <i>P</i> = 0.024 and TC/CC vs. TT: adjusted OR = 2.26, 95% CI = 1.15-4.43, <i>P</i> = 0.018).
|
29100337 |
2017 |
|
Malignant neoplasm of breast
|
|
0.010 |
GeneticVariation
|
BEFREE |
In contrast, the -1661A>G (rs4553808) polymorphism increased breast cancer risk in allelic, heterozygous and dominant models, whereas -1722 T>C (rs733618) did not relate to breast cancer risk.
|
28097051 |
2017 |
|
Lupus Erythematosus, Systemic
|
|
0.010 |
GeneticVariation
|
BEFREE |
But -1722T/C (rs733618) was significantly associated with SLE both in allele {fixed: OR: 0.699, 95% CI: (0.602-0.811), p = 0.000; random: OR: 0.748, 95% CI: (0.565-0.990), p = 0.042} and in genotype {CC/(CT+TT)} meta-analysis {OR: 0.422, 95% CI: (0.297-0.598), p = 0.000}.
|
23261408 |
2013 |
|
Drug-Induced Liver Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Five haplotypes were estimated for 4 SNPs (excluding rs733618); the frequency of haplotype ACGG was significantly higher in the DILI group (68.9%) than in the non-DILI group (61.1%) (p = 0.041).
|
23300559 |
2012 |
|
Filarial Elephantiases
|
|
0.010 |
GeneticVariation
|
BEFREE |
LF carriers of the rs733618 AG genotypes (p = 0.02) and those with combined minor allele G carriers (AG + GG; p = 0.01) exhibited a significantly decreased risk for LF.
|
21513760 |
2011 |
|
Graves Disease
|
|
0.010 |
GeneticVariation
|
BEFREE |
Association of GD with a novel risk SNP at the 5' upstream region, CTLA4_-1722_T/C (rs733618), was demonstrated (P=0.0096).
|
18059468 |
2008 |